BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guo S, Qiu L, Chen Y, Wang X, Ma B, Qu C, Cui J, Zhang H, Xing C, Zhan Y, An H. TMEM16A-inhibitor loaded pH-responsive nanoparticles: A novel dual-targeting antitumor therapy for lung adenocarcinoma. Biochem Pharmacol 2020;178:114062. [PMID: 32492446 DOI: 10.1016/j.bcp.2020.114062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chang L, Chang R, Shen J, Wang Y, Song H, Kang X, Zhao Y, Guo S, Qin J. Self-healing pectin/cellulose hydrogel loaded with limonin as TMEM16A inhibitor for lung adenocarcinoma treatment. Int J Biol Macromol 2022;219:754-66. [PMID: 35961552 DOI: 10.1016/j.ijbiomac.2022.08.037] [Reference Citation Analysis]
2 Guo S, Bai X, Shi S, Li S, Liu X, An H, Kang X. Multi-target tracheloside and doxorubicin combined treatment of lung adenocarcinoma. Biomed Pharmacother 2022;153:113392. [PMID: 35834992 DOI: 10.1016/j.biopha.2022.113392] [Reference Citation Analysis]
3 Bai X, Li S, Liu X, An H, Kang X, Guo S. Caffeic Acid, an Active Ingredient in Coffee, Combines with DOX for Multitarget Combination Therapy of Lung Cancer. J Agric Food Chem 2022. [PMID: 35772797 DOI: 10.1021/acs.jafc.2c03009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kaushik N, Borkar SB, Nandanwar SK, Panda PK, Choi EH, Kaushik NK. Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. J Nanobiotechnology 2022;20:152. [PMID: 35331246 DOI: 10.1186/s12951-022-01364-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
5 Bai X, Liu X, Li S, An H, Kang X, Guo S. Nuciferine Inhibits TMEM16A in Dietary Adjuvant Therapy for Lung Cancer. J Agric Food Chem 2022. [PMID: 35298888 DOI: 10.1021/acs.jafc.1c08375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
6 Guo S, Bai X, Shi S, Deng Y, Kang X, An H. TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment. Int J Mol Sci 2021;22:10930. [PMID: 34681590 DOI: 10.3390/ijms222010930] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Guo S, Bai X, Liu Y, Shi S, Wang X, Zhan Y, Kang X, Chen Y, An H. Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma. Front Pharmacol 2021;12:643489. [PMID: 33935737 DOI: 10.3389/fphar.2021.643489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
8 Shi S, Guo S, Chen Y, Sun F, Pang C, Ma B, Qu C, An H. Molecular mechanism of CaCCinh-A01 inhibiting TMEM16A channel. Arch Biochem Biophys 2020;695:108650. [PMID: 33132191 DOI: 10.1016/j.abb.2020.108650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mo SJ, Zhao HC, Tian YZ, Zhao HL. The Role of Prefoldin and Its Subunits in Tumors and Their Application Prospects in Nanomedicine. Cancer Manag Res 2020;12:8847-56. [PMID: 33061580 DOI: 10.2147/CMAR.S270237] [Cited by in F6Publishing: 2] [Reference Citation Analysis]